Who are IDEXX Laboratories's decision-makers?
IDEXX Laboratories is led by Jay Mazelsky. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Jay Mazelsky
- CFO/key exec
- Brian McKeon
- Founded
- 1983
- Employees
- 11,000+
- HQ
- Westbrook, ME
- Status
- Nasdaq: IDXX
- Jay MazelskyPresident and Chief Executive OfficerCEO since 2019Leads companion-animal diagnostics, software, and recurring-revenue growth.
- Brian McKeonExecutive Vice President and Chief Financial OfficerCFO since 2003Oversees finance and capital allocation.
- Michael LaneExecutive Vice President and General Manager, Reference Laboratories and TelemedicineSenior business leaderRuns key laboratory and telemedicine operations.
- Michael SchreckExecutive Vice President and Chief Commercial OfficerCommercial leaderLeads global commercial execution.
Who leads IDEXX Laboratories?
IDEXX Laboratories's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at IDEXX Laboratories?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is IDEXX Laboratories organized as it scales?
IDEXX Laboratories operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:IDEXX Laboratories leadershipIDEXX Laboratories annual reports
IDEXX Laboratories — frequently asked questions
